Pembrolizumab in Patients with Metastatic Breast Cancer with High Tumor Mutational Burden: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai S. Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra, Carmen J. Calfa, Maged F. Khalil, Eugene R. Ahn, Timothy L. Cannon, Pamela Crilley, Julie G. Fisher, Derrick S. Haslem, Sagun Shrestha, Kaitlyn R. Antonelli, Nicole L. Butler, Sasha L. Warren, Andrew L. Rygiel, Shamika Ranasinghe, Suanna S. Bruinooge, Richard L. Schilsky

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab in Patients with Metastatic Breast Cancer with High Tumor Mutational Burden: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study'. Together they form a unique fingerprint.

Medicine & Life Sciences